Day: November 18, 2020

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.The company will also present updated monotherapy...

IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of Software as a Service (SaaS), engineering services and intelligent hardware for the Internet of Things (IoT) and Remote Environment Management (REM), today announced that its engineering team supported Youbiquo, an Italy-based developer of wearable electronics and IoT devices, in the development of Youbiquo’s Talens Holo Augmented Reality Smart Glasses. Utilizing Lantronix’s Open-Q 626 Micro System on Module (µSOM) based on the Qualcomm® APQ8053-Pro System on Chip (SoC), Youbiquo was able to jumpstart the design and quickly go to market with a globally certified device. See the case study here.“Utilizing Lantronix’s unique Open-Q 626 micro SOM technology, we were able to create the Talens Holo Augmented Reality Smart Glasses to help...

TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) — PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce it has entered into an exclusive research collaboration agreement with Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for unmet medical needs, to expand Revive’s development plans with psilocybin to treat cancer and to discover novel uses of undisclosed psychedelic compounds.PharmaTher recently announced the filing of a U.S. provisional patent application outlining the potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™, PharmaTher’s...

Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine groupEfficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achievedData demonstrates vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%Companies plan to submit within days to the FDA for EUA and share data with other regulatory...

Innovative TRAXX locomotives enable CFL cargo to operate non-stop between Central Europe and FranceA breakthrough for the European East-West freight corridor, authorization also covers Belgium and LuxembourgBERLIN and LUXEMBOURG, Nov. 18, 2020 (GLOBE NEWSWIRE) —Note to editors: To view the photo associated with this press release, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/7fb7ac03-37ba-4e73-a13b-8d881b5219fcMobility solution provider Bombardier Transportation signed a contract with the Luxembourg based railway undertaking CFL cargo for 10 innovative BOMBARDIER TRAXX MS1 locomotives.The new locomotives represent a major leap towards the successful future of integrated rail freight transport in Europe as they will enable seamless cross-border transport from Central Europe to France. The locomotives...

Les locomotives novatrices TRAXX permettent à CFL cargo d’opérer des trains de bout en bout entre l’Europe centrale et la France.Une belle avancée pour le corridor de transport de marchandises est-ouest de l’Europe : l’autorisation couvre également la France, la Belgique et le Luxembourg.BERLIN et LUXEMBOURG, 18 nov. 2020 (GLOBE NEWSWIRE) —Note aux rédacteurs : Pour voir la photo associée à ce communiqué, veuillez visiter le lien suivant : https://www.globenewswire.com/NewsRoom/AttachmentNg/7fb7ac03-37ba-4e73-a13b-8d881b5219fc/frLe fournisseur de solutions de mobilité Bombardier Transport a signé un contrat avec l’entreprise ferroviaire luxembourgeoise CFL cargo pour l’achat de dix locomotives novatrices BOMBARDIER TRAXX MS1.Ces nouvelles locomotives représentent une avancée majeure pour l’avenir du transport ferroviaire de marchandises...

Innovative Lokomotiven ermöglichen CFL cargo den Non–Stop-Betrieb zwischen Mitteleuropa und FrankreichEin Durchbruch für den europäischen Ost-West-Güterverkehrskorridor. Die Zulassung umfasst auch Belgien und Luxemburg.BERLIN und LUXEMBURG, Nov. 18, 2020 (GLOBE NEWSWIRE) —Foto zu dieser Pressemitteilung finden Sie unter den folgenden Link: https://www.globenewswire.com/NewsRoom/AttachmentNg/7fb7ac03-37ba-4e73-a13b-8d881b5219fc/deDer Anbieter von Mobilitätslösungen Bombardier Transportation hat mit dem luxemburgischen Eisenbahnverkehrsunternehmen CFL cargo einen Vertrag über 10 innovative BOMBARDIER TRAXX MS1-Lokomotiven unterzeichnet.Die neuen Lokomotiven sind ein Meilenstein auf dem Weg in die erfolgreiche Zukunft des integrierten Schienengüterverkehrs in Europa, weil sie einen nahtlosen grenzüberschreitenden Verkehr von...